WallStreetZenWallStreetZen

NASDAQ: IMNM
Immunome Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMNM

Based on 5 analysts offering 12 month price targets for Immunome Inc

Min Forecast
$33.00+37.67%
Avg Forecast
$36.40+51.86%
Max Forecast
$40.00+66.88%

Should I buy or sell IMNM stock?

Based on 5 analysts offering ratings for Immunome Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IMNM's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IMNM as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their IMNM stock forecasts and price targets.

IMNM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-10
lockedlocked$00.00+00.00%2026-08-12
lockedlocked$00.00+00.00%2026-08-12
lockedlocked$00.00+00.00%2026-05-28
lockedlocked$00.00+00.00%2026-05-15

1 of 1

Forecast return on equity

Is IMNM forecast to generate an efficient return?

Company
9.13%
Industry
21.25%
Market
168.71%
IMNM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMNM forecast to generate an efficient return on assets?

Company
8.48%
Industry
23.75%
IMNM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMNM earnings per share forecast

What is IMNM's earnings per share in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
-$2.42
Avg 2 year Forecast
-$2.58
Avg 3 year Forecast
-$1.56

IMNM revenue forecast

What is IMNM's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$340.0k
Avg 2 year Forecast
$52.2M
Avg 3 year Forecast
$210.1M

IMNM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMNM$23.97$36.40+51.86%Strong Buy
NAMS$22.49$51.00+126.77%Buy
IRON$69.53$97.75+40.59%Strong Buy
PGEN$7.78$14.50+86.38%Buy
NRIX$25.44$34.67+36.27%Strong Buy
View Top Biotech Stocks

Immunome Stock Forecast FAQ

Is Immunome Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: IMNM) stock is to Strong Buy IMNM stock.

Out of 5 analysts, 2 (40%) are recommending IMNM as a Strong Buy, 3 (60%) are recommending IMNM as a Buy, 0 (0%) are recommending IMNM as a Hold, 0 (0%) are recommending IMNM as a Sell, and 0 (0%) are recommending IMNM as a Strong Sell.

If you're new to stock investing, here's how to buy Immunome stock.

What is IMNM's earnings growth forecast for 2026-2028?

(NASDAQ: IMNM) Immunome's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.

Immunome's earnings in 2026 is -$254,323,000.On average, 16 Wall Street analysts forecast IMNM's earnings for 2026 to be -$275,028,229, with the lowest IMNM earnings forecast at -$284,943,556, and the highest IMNM earnings forecast at -$245,668,412. On average, 16 Wall Street analysts forecast IMNM's earnings for 2027 to be -$292,655,477, with the lowest IMNM earnings forecast at -$322,787,622, and the highest IMNM earnings forecast at -$231,357,630.

In 2028, IMNM is forecast to generate -$177,669,485 in earnings, with the lowest earnings forecast at -$267,134,583 and the highest earnings forecast at -$85,864,688.

What is IMNM's revenue growth forecast for 2026-2028?

(NASDAQ: IMNM) Immunome's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Immunome's revenue in 2026 is $0.On average, 15 Wall Street analysts forecast IMNM's revenue for 2026 to be $38,616,053, with the lowest IMNM revenue forecast at $0, and the highest IMNM revenue forecast at $477,026,042. On average, 14 Wall Street analysts forecast IMNM's revenue for 2027 to be $5,926,480,681, with the lowest IMNM revenue forecast at $1,558,285,070, and the highest IMNM revenue forecast at $13,090,957,519.

In 2028, IMNM is forecast to generate $23,858,116,748 in revenue, with the lowest revenue forecast at $8,904,486,114 and the highest revenue forecast at $42,467,811,259.

What is IMNM's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IMNM) forecast ROA is 8.48%, which is lower than the forecast US Biotechnology industry average of 23.75%.

What is IMNM's Price Target?

According to 5 Wall Street analysts that have issued a 1 year IMNM price target, the average IMNM price target is $36.40, with the highest IMNM stock price forecast at $40.00 and the lowest IMNM stock price forecast at $33.00.

On average, Wall Street analysts predict that Immunome's share price could reach $36.40 by Sep 10, 2027. The average Immunome stock price prediction forecasts a potential upside of 51.86% from the current IMNM share price of $23.97.

What is IMNM's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IMNM) Immunome's current Earnings Per Share (EPS) is -$2.53. On average, analysts forecast that IMNM's EPS will be -$2.42 for 2026, with the lowest EPS forecast at -$2.51, and the highest EPS forecast at -$2.16. On average, analysts forecast that IMNM's EPS will be -$2.58 for 2027, with the lowest EPS forecast at -$2.84, and the highest EPS forecast at -$2.04. In 2028, IMNM's EPS is forecast to hit -$1.56 (min: -$2.35, max: -$0.76).

What is IMNM's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IMNM) forecast ROE is 9.13%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.